Ethanol intake increases galanin mRNA in the hypothalamus and withdrawal decreases it.
Alcoholism can be viewed as a motivational disorder that results from alterations in brain systems for ingestive behavior. Therefore, it was hypothesized that alcohol intake might alter the expression of hypothalamic peptides that stimulate feeding. Earlier studies showed that hypothalamic injection of the feeding-stimulatory peptide, galanin (GAL), increases the release of dopamine (DA) in the nucleus accumbens (NAc), as does systemic alcohol, leading to a focus on GAL. Results of this study demonstrate the following: (1). Ethanol, injected daily (0.8 g/kg 10% v/v) for 7 days in male rats, markedly increased the expression of GAL but not of neuropeptide Y (NPY). This occurred in specific hypothalamic nuclei, namely the dorsomedial nucleus (DMN), paraventricular nucleus (PVN) and perifornical lateral hypothalamus (PLH). (2). Rats induced to drink ethanol ad libitum, by gradually increasing the concentration from 1% to 9% v/v without adding sugar or flavoring, exhibited a similar stimulation of GAL mRNA in the PVN and GAL immunoreactivity in the DMN and PVN. (3). Rats given increasing ethanol concentrations, with 12 h access starting 4 h into the dark cycle, had a mean blood alcohol concentration of 18 mg/dl and exhibited a similar increase in GAL expression in the DMN and PVN. (4) Withdrawal from the opioid effects of 9% ethanol, produced by injection of naloxone (3 mg/kg sc), reversed this ethanol effect by significantly reducing GAL expression in the DMN and PLH below baseline levels. These studies suggest a possible role for hypothalamic GAL in alcohol abuse.
Leibowitz
Sarah F
SF
Laboratory of Behavioral Neurobiology, Rockefeller University, New York, NY 10021, USA.
Avena
Nicole M
NM
Chang
Guo-Qing
GQ
Karatayev
Olga
O
Chau
David T
DT
Hoebel
Bartley G
BG
D000428:Alcohol Drinking / Q000235:genetics* / Q000473:pathology; D000437:Alcoholism / Q000235:genetics* / Q000473:pathology; D000818:Animals; D001931:Brain Mapping; D004298:Dopamine / Q000378:metabolism; D000431:Ethanol / Q000097:blood / Q000633:toxicity*; D005260:Female; D019004:Galanin / Q000235:genetics*; D005786:Gene Expression Regulation / Q000187:drug effects / Q000502:physiology; D007031:Hypothalamus / Q000187:drug effects / Q000473:pathology*; D008297:Male; D009714:Nucleus Accumbens / Q000187:drug effects / Q000473:pathology; D012333:RNA, Messenger / Q000235:genetics*; D051381:Rats; D017207:Rats, Sprague-Dawley; D013375:Substance Withdrawal Syndrome / Q000235:genetics* / Q000473:pathology
D012333:RNA, Messenger; D000431:Ethanol; D019004:Galanin; D004298:Dopamine